Heart failure & cardiomyopathiesCohort study
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization
- Observational longitudinal cohort study
- multinational
- electronic health records or claims data
Authors' conclusion
Incident post-hHF rehospitalization risks and costs were high, and GDMT use changed little in the year following discharge
Study context
- Population
- Adults with a first heart failure (HF) hospitalization discharge, 2018–2022, in Japan, Sweden, UK and US
- Participants
- 263,525 adults
Main finding
As reported in the abstract
1-year death and rehospitalization rates per 100 patient-years after first HF hospitalization · 1 year
Died within first year
28%
Death ER per 100 patient-years
28.4 (95% CI: 27.0-29.9)
HF rehospitalization ER per 100 patient-years
13.6 (95% CI: 9.8-17.4)
CKD rehospitalization ER per 100 patient-years
4.5 (95% CI: 3.6-5.3)
Observational data: associations, not effects.
Further findings
Hospital health care costs
- Costs predominantly driven by HF and CKD
Guideline-directed medical therapy (GDMT) use, 2020–2022
- Uptake of SGLT2 inhibitors increased
- 2- to 7-fold
- Use of RAS inhibitors, sacubitril/valsartan, beta-blockers and MRA changed little
Original publication
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization. JACC Heart Fail. Published 21 June 2023. doi:10.1016/j.jchf.2023.04.017
Summarised from the published abstract; every number is checked against it